208 E7777 (denileukin diftitox) enhances anti-tumor activity and significantly extends survival benefit of anti-PD-1 in syngeneic solid tumor models

208 E7777 (denileukin diftitox) enhances anti-tumor activity and significantly extends survival benefit of anti-PD-1 in syngeneic solid tumor models

Bibliographic Details
Main Authors:	Mary Woodall-Jappe, A Raghav Chari, Anil Namboodiripad, Chandrasekhar Goda
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

Targeting regulatory T cells by E7777 enhances CD8 T-cell–mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models
by: Haider S. Mahdi, et al.
Published: (2023-10-01)

Production of Recombinant Denileukin Diftitox: Assessment in the Lab-scale Bioreactor
by: Seyed Morteza Robatjazi, et al.
Published: (2019-08-01)

Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma
by: Frederick Lansigan, et al.
Published: (2010-02-01)

Successful Treatment of Primary Cutaneous Anaplastic Large Cell Lymphoma with Denileukin Diftitox
by: Mayuko Amagai, et al.
Published: (2022-08-01)

Advanced-Stage Primary Cutaneous T-Cell Lymphoma Treated with Bexarotene and Denileukin Diftitox
by: Iván Cervigón-González, et al.
Published: (2011-02-01)

Molecular Docking and In Silico Study of Denileukin Diftitox: Comparison of Wild Type With C519S Mutant
by: Mohamad Najarasl, et al.
Published: (2020-05-01)

Primary cutaneous anaplastic large-cell lymphoma: Complete remission for 13 years after denileukin diftitox
by: Daniel J. Lewis, BA, et al.
Published: (2017-11-01)

Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma
by: Telang Sucheta, et al.
Published: (2011-12-01)

1154 Anti-PD-L1 antibody-immune modulator conjugates significantly enhance anti-tumor activity in syngeneic models
by: Chul-Woong Chung, et al.
Published: (2023-11-01)

Anti-tumor effect of aquaporin 3 monoclonal antibody on syngeneic mouse tumor model
by: Manami Tanaka, et al.
Published: (2022-10-01)

Tumor-immune profiling of CT-26 and Colon 26 syngeneic mouse models reveals mechanism of anti-PD-1 response
by: Yosuke Sato, et al.
Published: (2021-11-01)

Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models
by: Yanxia Li, et al.
Published: (2022-01-01)

Comparison of cisplatin-induced anti-tumor response in CT26 syngeneic tumors of three BALB/c substrains
by: Jeong Eun Gong, et al.
Published: (2021-12-01)

600 BR101801 stimulates anti-tumor immunity and enhances the efficacy of radiation in a syngeneic model
by: Seung Hyun Lee, et al.
Published: (2021-11-01)

1056 XTX301, a tumor activated, half-life extended IL-12 promoted potent anti-tumor immunity and activity across multiple syngeneic tumor models
by: Wilson Guzman, et al.
Published: (2023-11-01)

IL-2 and Anti-TGF-β Promote NK Cell Reconstitution and Anti-tumor Effects after Syngeneic Hematopoietic Stem Cell Transplantation
by: Maite Alvarez, et al.
Published: (2020-10-01)

Altered subcellular and submitochondrial localization of CTP:phosphatidate cytidylyltransferase in the Morris 7777 hepatoma.
by: K Y Hostetler, et al.
Published: (1978-07-01)

Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy
by: Xiang Yan, et al.
Published: (2018-01-01)

Combination Therapy of Novel Oncolytic Adenovirus with Anti-PD1 Resulted in Enhanced Anti-Cancer Effect in Syngeneic Immunocompetent Melanoma Mouse Model
by: Mariangela Garofalo, et al.
Published: (2021-04-01)

Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors.
by: Denis R Beckford Vera, et al.
Published: (2018-01-01)

Primary tumor-induced immunity eradicates disseminated tumor cells in syngeneic mouse model
by: Raziye Piranlioglu, et al.
Published: (2019-03-01)

Characterization of immune cell populations in syngeneic murine tumor models
by: Sofie Snipstad, et al.
Published: (2023-05-01)

Radiofrequency ablation in combination with CD73 inhibitor AB680 reduces tumor growth and enhances anti-tumor immunity in a syngeneic model of pancreatic ductal adenocarcinoma
by: Erika Y. Faraoni, et al.
Published: (2022-09-01)

723 WTX-613, a conditionally activated IFNα INDUKINE™ molecule, induces anti-tumor immune responses resulting in strong tumor growth control in syngeneic mouse tumor models
by: Christopher Nirschl, et al.
Published: (2021-11-01)

Anti-Tumor Potential of Post-Translational Modifications of PD-1
by: Xiaoming Xi, et al.
Published: (2024-03-01)

Sintilimab: A Promising Anti-Tumor PD-1 Antibody
by: Lin Zhang, et al.
Published: (2020-11-01)

A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity
by: Diana I. Albu, et al.
Published: (2024-12-01)

Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo
by: Maohua Li, et al.
Published: (2021-03-01)

Anti-Tumor Efficacy of Anti-PD-1/PD-L1 Antibodies in Combination With Other Anticancer Drugs in Solid Tumors: A Systematic Review and Meta-Analysis
by: Takashi Inoue MS, et al.
Published: (2022-11-01)

PA-MSHA induces inflamed tumor microenvironment and sensitizes tumor to anti-PD-1 therapy
by: Min Huang, et al.
Published: (2022-11-01)

Cimetidine Attenuates Therapeutic Effect of Anti-PD-1 and Anti-PD-L1 and Modulates Tumor Microenvironment in Colon Cancer
by: Feng-Chi Kuo, et al.
Published: (2024-03-01)

Tumor-localized catalases can fail to alter tumor growth and transcriptional profiles in subcutaneous syngeneic mouse tumor models
by: Allison Sheen, et al.
Published: (2023-08-01)

Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China
by: Lin Zhang, et al.
Published: (2022-01-01)

Tumor immune microenvironment characterization and response to anti-PD-1 therapy
by: Mariacarmela Santarpia, et al.
Published: (2015-06-01)

Syngeneic tobacco carcinogen–induced mouse lung adenocarcinoma model exhibits PD-L1 expression and high tumor mutational burden
by: Laura P. Stabile, et al.
Published: (2021-02-01)

Curcumin, but not Prima-1, decreased tumor cell proliferation in the syngeneic murine orthotopic bladder tumor model
by: Fábio T. Watanabe, et al.
Published: (2011-01-01)

Anti-PD-1 antibody armored γδ T cells enhance anti-tumor efficacy in ovarian cancer
by: Yue Wang, et al.
Published: (2023-10-01)

Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1
by: Mukherjee, D, et al.
Published: (2023)

Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1
by: Debayan Mukherjee, et al.
Published: (2023-12-01)

Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes
by: Thomas Morgan Hulen, et al.
Published: (2023-06-01)